# Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT01701323** · PHASE1 · TERMINATED · sponsor: **Nohla Therapeutics, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Acute Leukemia of Ambiguous Lineage
- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion
- **DRUG:** Cytarabine
- **DRUG:** Filgrastim
- **DRUG:** Fludarabine Phosphate

## Key facts

- **NCT ID:** NCT01701323
- **Lead sponsor:** Nohla Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12-10
- **Primary completion:** 2018-05-10
- **Final completion:** 2018-05-10
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-03-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01701323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01701323, "Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01701323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*